Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SYNTHETIC CHEMICALS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. BIOPHARMACEUTICALS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. OTHERS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. CHRONIC & AUTOIMMUNE DISEASES 

5.2.1. Market size and forecast

5.3. ONCOLOGY

5.3.1. Market size and forecast

5.4. OTHERS

5.4.1. Market size and forecast

Chapter: 6 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Biosimilar Monoclonal Antibodies Market by Type
6.2.5. North America Biosimilar Monoclonal Antibodies Market by Application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Biosimilar Monoclonal Antibodies Market by Type
6.3.5. Europe Biosimilar Monoclonal Antibodies Market by Application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type
6.4.5. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Biosimilar Monoclonal Antibodies Market by Type
6.5.5. LAMEA Biosimilar Monoclonal Antibodies Market by Application

Chapter: 7 COMPANY PROFILES

7.1. BIOCON 

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. ACCORD HEALTHCARE 

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. AET BIOTECH 

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. AMGEN

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. CELLTRION 

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. DR. REDDY'S LABORATORIES 

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. HOSPIRA 

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. 3SBIO 

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. ALLERGAN 

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. ALVARTIS PHARMA 

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments